TCG Crossover Management, LLC
PALO ALTO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$3.54B2026 Q3
Positions57
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.53.3%
What Changed This Quarter?
Top Holdings
ABVX
Abivax S.A.
10.2%
CGON
CG Oncology
7.4%
AMLX
Amylyx Pharmaceuticals
5.1%
SYRE
Spyre Therapeutics
4.8%
TNGX
Tango Therapeutics
4.8%
ZLAB
Zai Lab
4.6%
IMVT
Immunovant
4.3%
DNTH
Dianthus Therapeutics
4.2%
New / Increased
8 new · 4 increased
KRSANEW
Korsana Biosciences
4.1%
ADRXNEW
Adarx Pharmaceuticals
2.3%
Entera BioNEW
Entera Bio
1.0%
TARSNEW
Tarsus Pharmaceuticals
0.9%
OBXNEW
Obsidian Therapeutics
0.9%
TYRA
Tyra Biosciences
2.1%
+7.0%
MIRM
Mirum Pharmaceuticals
2.7%
+5.4%
AURA
Aura Biosciences
1.8%
+6.6%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.